Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The use and performance of productivity scales to evaluate presenteeism in mood disorders.
Despiégel N, Danchenko N, François C, Lensberg B, Drummond MF. Despiégel N, et al. Value Health. 2012 Dec;15(8):1148-61. doi: 10.1016/j.jval.2012.08.2206. Value Health. 2012. PMID: 23244819 Free article. Review.
Challenges in measuring and valuing productivity costs, and their relevance in mood disorders.
Lensberg BR, Drummond MF, Danchenko N, Despiégel N, François C. Lensberg BR, et al. Among authors: despiegel n. Clinicoecon Outcomes Res. 2013 Nov 18;5:565-73. doi: 10.2147/CEOR.S44866. eCollection 2013. Clinicoecon Outcomes Res. 2013. PMID: 24273412 Free PMC article. Review.
Cost-Utility of Vortioxetine in the Treatment of Major Depressive Disorder: Comparison with Agomelatine, Bupropion, Sertraline and Venlafaxine in the Finnish Setting.
Soini EJ, Hallinen T, Brignone M, Despiégel N, Aalto-Setälä M, Danchenko N, Kolasa K. Soini EJ, et al. Among authors: despiegel n. Value Health. 2014 Nov;17(7):A459. doi: 10.1016/j.jval.2014.08.1267. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201284 Free article. No abstract available.
Cost-Effectiveness of Dolutegravir, a New Generation Integrase Inhibitor, in Hiv-1 Treatment Experienced Patients in France.
Despiégel N, Marcellin AG, Aubin C, Espinas C, Laurisse A, Pialoux G. Despiégel N, et al. Value Health. 2014 Nov;17(7):A678-9. doi: 10.1016/j.jval.2014.08.2526. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202502 Free article. No abstract available.
Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
Nordström G, Danchenko N, Despiegel N, Marteau F. Nordström G, et al. Value Health. 2012 Mar-Apr;15(2):231-9. doi: 10.1016/j.jval.2011.09.011. Epub 2012 Jan 27. Value Health. 2012. PMID: 22433753
Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA.
Stålhammar NO, Spiegel BM, Granstedt Löfman H, Karlsson M, Wahlqvist P, Næsdal J, Nelson MT, Despiégel N. Stålhammar NO, et al. Pragmat Obs Res. 2012 Dec 5;3:57-67. doi: 10.2147/POR.S36704. eCollection 2012. Pragmat Obs Res. 2012. PMID: 27774018 Free PMC article.
Participating sites were comprised of family practice (n = 30), internal medicine (n = 8), and specialist (gastroenterologist) centers (n = 15). ...
Participating sites were comprised of family practice (n = 30), internal medicine (n = 8), and specialist (gastroenterologist) …
Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N. Wade AG, et al. Pharmacoeconomics. 2008;26(11):969-81. doi: 10.2165/00019053-200826110-00008. Pharmacoeconomics. 2008. PMID: 18850765 Clinical Trial.
Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW, Lönn SL, Despiégel N. Lam RW, et al. Int Clin Psychopharmacol. 2010 Jul;25(4):199-203. doi: 10.1097/YIC.0b013e32833948d8. Int Clin Psychopharmacol. 2010. PMID: 20357664
29 results
Jump to page
Feedback